EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic and clinical response to diagnostic intravenous antiseizure medication trials

Markus Leitinger iD, Nicolas Gaspard iD, Lawrence J Hirsch iD, Sándor Beniczky iD, Peter W Kaplan, Khalil Husari, Eugen Trinka iD

Epilepsia · 2023-09 · 64 (9) · 2351-2360

DOI: 10.1111/epi.17694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 10.07.2023. Verfasst von Markus Leitinger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, member of European Reference Network EpiCARE, Center for Cognitive Neuroscience, Christian Doppler University Hospital, Para…. Hauptthemen laut MEDLINE: Status Epilepticus. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The Salzburg criteria for nonconvulsive status epilepticus (NCSE) and the American Clinical Neurophysiology Society (ACNS) Standardized Critical Care EEG Terminology 2021 include a diagnostic trial with intravenous (IV) antiseizure medications (ASMs) to assess electroencephalographic (EEG) and clinical response as a diagnostic criterion for definite NCSE and possible NCSE. However, how to perform this diagnostic test and assessing the EEG and clinical responses have not been operationally defined.

Methods

We performed a Delphi process involving six experts to standardize the diagnostic administration of IV ASM and propose operational criteria for EEG and clinical response.

Results

Either benzodiazepines (BZDs) or non‐BZD ASMs can be used as first choice for a diagnostic IV ASM trial. However, non‐BZDs should be considered in patients who already have impaired alertness or are at risk of respiratory depression. Levetiracetam, valproate, lacosamide, brivaracetam, or (if the only feasible drug) fosphenytoin or phenobarbital were deemed appropriate for a diagnostic IV trial. The starting dose should be approximately two thirds to three quarters of the full loading dose recommended for treatment of status epilepticus, with an additional smaller dose if needed. ASMs should be administered during EEG recording under supervision. A monitoring time of at least 15 min is recommended. If there is no response, a second trial with another non‐BDZ or BDZs may be considered. A positive EEG response is defined as the resolution of the ictal–interictal continuum pattern for at least three times the longest previously observed spontaneous interval of resolution (if any), but minimum of one continuous minute. For a clinical response, physicians should use a standardized examination before and after IV ASM administration. We suggest a definite time‐locked improvement in a focal deficit or at least one‐step improvement on a new dedicated one‐domain 10‐level NCSE response scale. Significance The proposed standardized approach of a diagnostic IV ASM trial further refines the ACNS and Salzburg diagnostic criteria for NCSE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Status EpilepticusHumansAdministration, IntravenousBenzodiazepinesElectroencephalographyPhenobarbitalClinical Trials as Topic

Stichwörter der Autor:innen

epilepsyictal-interictal continuumscale

Substanzen

BenzodiazepinesPhenobarbital

Autor:innen und Institutionen

  • Department of Neurology, member of European Reference Network EpiCARE, Center for Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria.
  • Neuroscience Institute, Center for Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria.
  • Hôpital Universitaire de Bruxelles-Hôpital Erasme, Brussels, Belgium.
  • Université Libre de Bruxelles, Brussels, Belgium.
  • Comprehensive Epilepsy Center, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Department of Clinical Neurophysiology, Danish Epilepsy Center, Dianalund, Denmark.

ORCID-Profile: Markus Leitinger, Nicolas Gaspard, Lawrence J Hirsch, Sándor Beniczky, Eugen Trinka

Zitieren

APA

Leitinger, M., Gaspard, N., Hirsch, L. J., Beniczky, S., Kaplan, P. W., Husari, K., & Trinka, E. (2023). Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic and clinical response to diagnostic intravenous antiseizure medication trials. Epilepsia, 64(9), 2351-2360. https://doi.org/10.1111/epi.17694

Vancouver

Leitinger M, Gaspard N, Hirsch LJ, Beniczky S, Kaplan PW, Husari K, et al. Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic and clinical response to diagnostic intravenous antiseizure medication trials. Epilepsia. 2023;64(9):2351-2360. doi:10.1111/epi.17694

BibTeX
@article{Leitinger2023,
  author = {Leitinger, Markus and Gaspard, Nicolas and Hirsch, Lawrence J and Beniczky, Sándor and Kaplan, Peter W and Husari, Khalil and Trinka, Eugen},
  title = {Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic and clinical response to diagnostic intravenous antiseizure medication trials},
  journal = {Epilepsia},
  year = {2023},
  volume = {64},
  number = {9},
  pages = {2351--2360},
  doi = {10.1111/epi.17694}
}
Kostenlos starten →